| P50 | author | Edmund Capparelli | Q87605095 |
| P2093 | author name string | Mark Mirochnick | |
| P2860 | cites work | The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites | Q71746290 |
| | Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules | Q72793341 |
| | The maternal-fetal transfer of lamivudine in the ex vivo human placenta | Q73143771 |
| | Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy | Q73464193 |
| | Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers | Q73508511 |
| | Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group | Q73711293 |
| | Induction of CYP2D6 in pregnancy | Q73846474 |
| | Pharmacokinetics of indinavir in HIV-positive pregnant women | Q73896502 |
| | Pharmacological implications of lengthened in-utero exposure to nevirapine | Q74023464 |
| | Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase | Q24629039 |
| | Management of human immunodeficiency virus infection in pregnancy | Q28204446 |
| | Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | Q28239283 |
| | 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity | Q28378894 |
| | Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. | Q30326359 |
| | Pharmacokinetics during pregnancy: evidence-based maternal dose formulation | Q30888520 |
| | Clinical pharmacokinetics of zidovudine. An overview of current data | Q31030044 |
| | Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women | Q31928400 |
| | Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir | Q31956952 |
| | Nelfinavir mesylate: a protease inhibitor | Q33592439 |
| | Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection | Q33631613 |
| | Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques | Q33752846 |
| | Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus | Q33754634 |
| | Antiretrovirals | Q33792042 |
| | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial | Q33873955 |
| | Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission | Q33958839 |
| | Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers | Q33980114 |
| | Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults | Q33980172 |
| | The use of anticonvulsants during pregnancy | Q34308706 |
| | Antidepressants during pregnancy and lactation: defining exposure and treatment issues | Q34308727 |
| | Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial | Q34503010 |
| | Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial | Q34719306 |
| | Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis | Q34736674 |
| | Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations | Q34738805 |
| | Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women | Q35547832 |
| | Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication | Q35572889 |
| | The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir | Q35615609 |
| | Pharmacokinetics of nevirapine: initial single-rising-dose study in humans | Q35808226 |
| | Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). | Q38884920 |
| | A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). | Q38886823 |
| | Interactions of various 19-nor steroids with human placental microsomal cytochrome P-450 (P-450hpm) | Q39130612 |
| | Plasma protein binding of drugs in pregnancy | Q40242706 |
| | Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus | Q40283999 |
| | Developmental pharmacology and toxicology of anti‐HIV therapeutic agents: dideoxynucleosides 1 | Q40481228 |
| | In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus | Q40827877 |
| | Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection | Q41429010 |
| | Drug disposition in mother and foetus | Q41639067 |
| | Pharmacokinetic changes during pregnancy and their clinical relevance | Q41657026 |
| | Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. | Q42275525 |
| | Nucleoside transport by perfused human placenta | Q42287353 |
| | The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. | Q42613832 |
| | Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission | Q42681152 |
| | Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure | Q43816558 |
| | Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women | Q43822045 |
| | Myelomeningocele in a child with intrauterine exposure to efavirenz. | Q43864153 |
| | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. | Q43897601 |
| | Transplacental passage of protease inhibitors at delivery | Q43937448 |
| | Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). | Q43956302 |
| | CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid | Q43961554 |
| | Intracellular carbovir triphosphate levels in patients taking abacavir once a day. | Q43988883 |
| | Concentrations of protease inhibitors in cord blood after in utero exposure | Q44157151 |
| | Lopinavir protein binding in vivo through the 12-hour dosing interval | Q44746683 |
| | A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators | Q45740341 |
| | Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants | Q45746364 |
| | Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study | Q45746870 |
| | Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring | Q45753331 |
| | Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team | Q45754372 |
| | The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi | Q45779956 |
| | Zidovudine response relationships in early human immunodeficiency virus infection | Q45783462 |
| | High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection | Q45789390 |
| | Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion | Q48746218 |
| | Serum protein binding of drugs during and after pregnancy in humans. | Q51875039 |
| | Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. | Q54078500 |
| | Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group | Q64131586 |
| | Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound | Q67956898 |
| | Pharmacokinetic disposition of zidovudine during pregnancy | Q68184172 |
| | Zidovudine Pharmacokinetics During Pregnancy | Q68200727 |
| | Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women | Q68692669 |
| | Azidothymidine (zidovudine) transport by the human placenta | Q68696399 |
| | Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases | Q68942769 |
| | Induction of hepatic enzymes during normal human pregnancy | Q69563563 |
| | Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients | Q69720906 |
| | Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs | Q70613187 |
| | Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole | Q71117298 |
| | Drug disposition and pharmacokinetics in the maternal-placental-fetal unit | Q71314217 |
| | Rapid gentamicin elimination in obstetric patients | Q71374460 |
| P433 | issue | 15 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pregnant person | Q104720811 |
| | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 1071-1087 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetics of antiretrovirals in pregnant women | |
| P478 | volume | 43 | |